left-arrow right-arrow pinterest facebook google_plus linkedin

SWOG S1706


Recruiting | Phase II

Official Title:

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Study Purpose:

To determine if adding the drug olaparib to the usual radiation therapy for inflammatory breast cancer will decrease the risk of cancer returning.


  • Olaparib (Lynparza®)
  • Radiation Therapy
  • Lab Biomarker Analysis
  • ARM I: Olaparib 25mg BID + Standard Radiation Therapy
  • ARM II: Radiation Therapy Alone

Patients will be followed every 3 months from start of study for the first 3 years, and then every 6 months until 8 years from start of study.

Key Participation Requirements: 


Male or female


19 years and older


Breast cancer patients who have had surgery and whose cancer is diagnosed as inflammatory.

Marker Status:

All ER/PR/Her2 statuses are accepted


Must have completed chemotherapy before mastectomy, as well as the mastectomy, itself.

They may or may not have had chemotherapy after surgery.

Must be registered to the study at least 3 weeks, but no more than 12 weeks after mastectomy.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

SWOG S1706

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!